Cantor Fitzgerald Reduces Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of Humacyte in a research note issued on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($1.41) for the year, down from their previous estimate of ($1.23). Cantor Fitzgerald has a "Overweight" rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.18) per share.

A number of other equities analysts have also recently issued reports on HUMA. TD Cowen restated a "buy" rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Benchmark reissued a "buy" rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Humacyte in a report on Wednesday. Finally, EF Hutton Acquisition Co. I upgraded Humacyte to a "strong-buy" rating in a research note on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of "Buy" and an average price target of $11.00.

Humacyte Trading Down 9.4 %

NASDAQ HUMA traded down $0.50 during trading hours on Thursday, hitting $4.84. 7,901,000 shares of the company's stock were exchanged, compared to its average volume of 2,391,228. The firm has a market cap of $577.65 million, a price-to-earnings ratio of -3.66 and a beta of 1.47. The stock has a 50-day simple moving average of $5.44 and a 200 day simple moving average of $6.17. The company has a current ratio of 1.10, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 1-year low of $2.35 and a 1-year high of $9.97.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 157,704 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now owns 3,519,558 shares of the company's stock, valued at approximately $19,076,004.36. This trade represents a 4.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Brady W. Dougan sold 252,676 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 5.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura E. Niklason sold 157,704 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $5.42, for a total transaction of $854,755.68. Following the completion of the sale, the chief executive officer now directly owns 3,519,558 shares of the company's stock, valued at $19,076,004.36. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last three months. Corporate insiders own 11.20% of the company's stock.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. nVerses Capital LLC bought a new stake in Humacyte during the second quarter worth $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte during the 3rd quarter worth $75,000. Principal Financial Group Inc. purchased a new position in shares of Humacyte in the 2nd quarter worth about $83,000. FORA Capital LLC bought a new position in Humacyte during the third quarter valued at about $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte in the second quarter valued at $97,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.